menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Daiichi Sankyo Light on Inequalities and Unmet Needs With Cardio Disease

    BUSINESSWIRE

    New Japanese Patent For Edoxaban

    PRESS RELEASE

    The dossier of Edoxaban is available for B2B partners!

    PRESS RELEASE

    Four-year follow-up data reinforces the safety of treatment with edoxaban

    BUSINESSWIRE

    USDMF for Edoxaban API has been submitted Based On Our Process Expertise

    PRESS RELEASE

    Zydus`s Generic Edoxaban Receives Approval in the U.S.

    FDA

    Data strengthens important role of LIXIANA in patient with atrial fibrillation

    BUSINESSWIRE

    Edoxaban Noninferior to Warfarin in Atrial Fibrillation After TAVI

    ESCARDIO

    New data support the use of LIXIANA ® in patients with atrial fibrillation (AF)

    BUSINESSWIRE

    New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA®

    BUSINESSWIRE

    Daiichi submits application in Japan for expanded usage for anticoagulant

    PHARMABIZ

    Results of 12-month analysis data from ETNA-AF non-interventional study out

    PRNEWSWIRE

    Daiichi Sankyo phase 3 study of anticoagulant, edoxaban meets primary endpoint

    PHARMABIZ

    New 12-month analysis data from ETNA-AF non-interventional study

    PRNEWSWIRE

    ETNA-AF-Europe Registry Data on LIXIANA®?(edoxaban) Published

    PRNEWSWIRE

    Rates of Bleeding and Venous (VTE) Events Reported After 12 Months of Edoxaban

    PRNEWSWIRE

    European Results From Global ETNA-AF Registry Show Low Bleeding

    PR NEWSWIRE

    Daiichi Sankyo announces positive results for Lixiana combination

    CLINICALTRIALSARENA

    Daiichi Sankyo Presents +ve Results of the ENTRUST-AF PCI Study of edoxaban

    PR NEWSWIR

    Daiichi-Sankyo, Bayer, Otsuka & Others Called Out for UK Advertisement Breaches

    RAPS

    FDA Confirms Paragraph IV Patent Challenge of Savaysa 206316 (Edoxaban Tosylate 15 mg, 30 mg and 60 mg) Tablets

    FDA

    List of New Paragraph IV Certifications as of March 13, 2019

    FDA

    AMAG Pharma to buy US-based biopharma company, Perosphere Pharmaceuticals

    PHARMABIZ

    List of centrally authorised products requiring a notification of a change for update of annexes

    EMA

    Daiichi Sankyo Presents Analyses from Global ETNA-AF Programme of Oral edoxaban

    PR NEWSWIRE

    Daiichi Sankyo & Menarini Enter Licensing Agreement for Commercializing LIXIANA®

    BUSINESSWIRE

    Following FDA win, Portola loses CEO William Lis

    ENDPTS

    Portola`s Andexxa bleeding antidote wins FDA nod

    FIERCE PHARMA

    Daiichi Sankyo takes another big whack at U.S. sales operations

    FIERCE PHARMA

    Daiichi Sankyo begins phase 3 ENVISAGE-TAVI AF study of once-daily Lixiana

    PHARMABIZ

    Daiichi Sankyo Europe GmbH Roteas (edoxaban) Receives Approval In Europe

    EMA

    Daiichi Sankyo begins clinical registry of venous thromboembolism

    PHARMABIZ

    Daiichi Sankyo, Inc. Announces New Analyses of Once-Daily SAVAYSA® (edoxaban)

    PR NEWSWIRE

    Six new medicines endorsed for EU approval

    PHARMATIMES

    Daiichi Sankyo phase 3b ENSURE-AF study of once-daily Lixiana in patients

    PHARMABIZ

    Servier Canada to market Daiichi Sankyo`s anti-coagulant edoxaban in Canada

    PHARMABIZ

    Daiichi caps layoffs drive by melding NJ ops into one smaller HQ

    FIERCE PHARMA

    Hoping to jump-start Lixiana, Daiichi Sankyo taps Merck for EU market assault

    FIERCE PHARMA MARKETING

    Daiichi Sankyo inks marketing pact with Daewoong Pharmaceutical

    BIOSPECTRUM ASIA

    Four therapies approved for use on NHS Scotland

    PHARMATIMES

    NICE recommends blood-thinning drug edoxaban

    EUROPEAN PHARMACEUTICAL REVIEW

    NICE recommends edoxaban for deep vein thrombosis

    EUROPEAN PHARMACEUTICAL REVIEW

    Daiichi clot-buster wins a NICE green light, but still faces an uphill track

    FIERCE PHARMA

    UK launch for Daiichi`s bloodthinner Lixiana

    PHARMATIMES

    Daiichi`s Lixiana (Edoxaban) Approved in EU For Stroke

    EMA

    Daiichi`s LIXIANA® (Edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular AF, DVT and PE

    DAIICHI SANKYO

    BMS` Opdivo backed as melanoma therapy in EU

    PM LIVE

    Eleven Medicines Leap Closer To Approval In Europe

    PHARMATIMES

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015

    EMA

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.